TITLE

Cardiometabolic Disorders

PUB. DATE
October 2009
SOURCE
Pharmaceutical Representative;Oct2009, Vol. 39 Issue 10, p18
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the links between cardiometabolic disorders such as obesity, diabetes, hypertension and lipid abnormalities. The National Heart, Lung and Blood Institute (NHLBI) reports that 25 percent of adults in the U.S. have abnormalities that are known as "syndrome X," "metabolic syndrome" or "insulin resistance syndrome," and they spend on cardiometabolic agents. The Web portal and the publications of Advanstar Communications Inc. introduced an initiative to address the issue.
ACCESSION #
44722406

 

Related Articles

  • Prevalence of the metabolic syndrome in patients with carotid disease according to NHLBI/AHA and IDF criteria: a cross-sectional study. Maksimovic, Milos Z.; Vlajinac, Hristina D.; Radak, Djordje J.; Marinkovic, Jelena M.; Jorga, Jagoda B. // BMC Cardiovascular Disorders;2012, Vol. 12 Issue 1, p1 

    Background: Metabolic syndrome (MetS) has been related to type 2 diabetes and cardiovascular diseases. Different criteria for diagnosis of MetS have been recommended, but there is no agreement about which criteria are best to use. The aim of the present study was to investigate agreement between...

  • CARDIOMETABOLIC DISORDERS & WEIGHT: ACTION FOR OUTCOMES.  // Medical Economics;9/4/2009, Vol. 86 Issue 17, p31 

    The article discusses the efforts of the life sciences publications and web portal of Advanstar Communications Inc. in addressing the growing cardiometabolic disorders and weight issues in the U.S. It states that the collaboration aims to address this major public health issue through conducting...

  • NHLBI stops AIM-HIGH trial. Elliott, William T. // Neurology Alert;Jul2011 Clinical Briefs in Primary, p2 

    The article reports that the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) clinical trial was prematurely stopped by the U.S. National Heart Lung and Blood Institute (NHLBI).

  • NHLBI stops AIM-HIGH trial.  // Infectious Disease Alert;Jul2011 Pharmacology Watch Supplemt, p2 

    The article reports on the decision of the National Heart Lung and Blood Institute (NHLBI) in the U.S. to stop the clinical trial titled Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (AIM-HIGH).

  • Your call to action. Burnett, Erich // Medical Economics;9/4/2009, Vol. 86 Issue 17, p10 

    The author reflects on the importance of taking actions in preventing end-stage diseases to improve the outcome of patients with cardiometabolic disease. He states that the National Heart, Lung, and Blood Institute is seeing the growing number of the patients who suffers from this disease. He...

  • Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article provides information on the 63 million U.S. dollars grants to the Minneapolis Heart Institute over the next seven years for research in cardiovascular cell therapy by the U.S. Cardiovascular Cell Therapy Research Network funded by the U.S. National Heart, Lung and Blood Institute.

  • Metabolic Syndrome: Increasing the risk for chronic disease.  // Charlotte Post;8/8/2013, Vol. 38 Issue 48, p1B 

    The article offers information on metabolic syndrome which, according to the National Heart, Lung and Blood Institute of the U.S., consists of high cholesterol, high fasting blood sugar and excess fat in abdominal area and discusses its effect and treatment.

  • AHA and NHLBI Review Diagnosis and Management of the Metabolic Syndrome. Armstrong, Carrie // American Family Physician;9/15/2006, Vol. 74 Issue 6, p1039 

    The article deals with the recommendations released by the American Heart Association and the National Heart, Lung, and Blood Institute on the management and diagnosis of the metabolic syndrome. It is said that metabolic syndrome is a constellation of interrelated metabolic risk factors. People...

  • Diuretics Most Effective Blood Pressure Medication for People with Metabolic Syndrome.  // Ethnicity & Disease;Spring2008, Vol. 18 Issue 2, p246 

    The article reports on a study from the National Heart, Lung, and Blood Institute (NHLBI), which examined the effectiveness of diuretics as blood pressure medication for people with metabolic syndrome. The study compared the use of diuretic with three other classes of medications to treat high...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics